EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The NAMPT Inhibitor FK866 in Combination with Cisplatin Reduces Cholangiocarcinoma Cells Growth

Kishor Pant iD, Seth Richard, Estanislao Peixoto iD, Jun Yin, Davis M Seelig, Pietro Carotenuto iD, Massimiliano Salati, Brunella Franco iD, Lewis R Roberts iD, Sergio A Gradilone iD

Cells · 28.02.2023 · 12 (5) · 775

DOI: 10.3390/cells12050775 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 28.02.2023. Verfasst von Kishor Pant und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Hormel Institute, University of Minnesota, Austin, MN 55912, USA. Hauptthemen laut MEDLINE: Cisplatin, Cholangiocarcinoma. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hormel Foundation, POR CAMPANIA FESR 2014/2020, Italian Association for Cancer Research (AIRC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

It is well established that Cholangiocarcioma (CCA) drug resistance plays a crucial role in the spread and survival of cancer cells. The major enzyme in the nicotinamide-adenine dinucleotide (NAD+)-mediated pathways, nicotinamide phosphoribosyltransferase (NAMPT), is essential for cancer cell survival and metastasis. Previous research has shown that the targeted NAMPT inhibitor FK866 reduces cancer cell viability and triggers cancer cell death; however, whether FK866 affects CCA cell survival has not been addressed before. We show herein that NAMPT is expressed in CCA cells, and FK866 suppresses the capacity of CCA cells to grow in a dose-dependent manner. Furthermore, by preventing NAMPT activity, FK866 significantly reduced the amount of NAD+ and adenosine 5′-triphosphate (ATP) in HuCCT1, KMCH, and EGI cells. The present study’s findings further show that FK866 causes changes in mitochondrial metabolism in CCA cells. Additionally, FK866 enhances the anticancer effects of cisplatin in vitro. Taken together, the results of the current study suggest that the NAMPT/NAD+ pathway may be a possible therapeutic target for CCA, and FK866 may be a useful medication targeting CCA in combination with cisplatin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinCholangiocarcinomaHumansNicotinamide PhosphoribosyltransferaseNADCell ProliferationAdenosine Triphosphate

Stichwörter der Autor:innen

CholangiocarcinomaFK866NADNAMPTcisplatin

Substanzen

CisplatinNicotinamide PhosphoribosyltransferaseNADAdenosine Triphosphate

Autor:innen und Institutionen

  • The Hormel Institute, University of Minnesota, Austin, MN 55912, USA.
  • Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
  • Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN 55905, USA.
  • Comparative Pathology Shared Resource, Masonic Cancer Center, College of Veterinary Medicine, University of Minnesota, St. Paul, MN 55108, USA.
  • Telethon Institute of Genetics and Medicine (TIGEM), 80078 Pozzuoli, Italy.
  • Medical Genetics, Department of Translational Medical Sciences, University of Naples Federico II, 80131 Naples, Italy.

ORCID-Profile: Kishor Pant, Estanislao Peixoto, Pietro Carotenuto, Brunella Franco, Lewis R Roberts, Sergio A Gradilone

Förderung

  • Hormel Foundation
  • POR CAMPANIA FESR 2014/2020
  • Italian Association for Cancer Research (AIRC)
  • AIRC
  • European Union’s Horizon 2020

Zitieren

APA

Pant, K., Richard, S., Peixoto, E., Yin, J., Seelig, D. M., Carotenuto, P., Salati, M., Franco, B., Roberts, L. R., & Gradilone, S. A. (2023). The NAMPT Inhibitor FK866 in Combination with Cisplatin Reduces Cholangiocarcinoma Cells Growth. Cells, 12(5), 775. https://doi.org/10.3390/cells12050775

Vancouver

Pant K, Richard S, Peixoto E, Yin J, Seelig DM, Carotenuto P, et al. The NAMPT Inhibitor FK866 in Combination with Cisplatin Reduces Cholangiocarcinoma Cells Growth. Cells. 2023;12(5):775. doi:10.3390/cells12050775

BibTeX
@article{Pant2023,
  author = {Pant, Kishor and Richard, Seth and Peixoto, Estanislao and Yin, Jun and Seelig, Davis M and Carotenuto, Pietro and Salati, Massimiliano and Franco, Brunella and Roberts, Lewis R and Gradilone, Sergio A},
  title = {The NAMPT Inhibitor FK866 in Combination with Cisplatin Reduces Cholangiocarcinoma Cells Growth},
  journal = {Cells},
  year = {2023},
  volume = {12},
  number = {5},
  pages = {775},
  doi = {10.3390/cells12050775}
}
Kostenlos starten →